Tag results:
cell transplantation
Mesenchymal Cell News
Emerging Concepts in the Treatment of Optic Neuritis: Mesenchymal Stem Cell-Derived Extracellular Vesicles
[Current Stem Cell Research & Therapy] Investigators review the potential application of MSC extracellular vesicles as an emerging treatment strategy for optic neuritis by reviewing studies in multiple sclerosis and related disorders.
Hematopoiesis News
Extracorporeal Membrane Oxygenation in Children Receiving Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: An International and Multidisciplinary Consensus Statement
[Lancet Child & Adolescent Health] The authors provide a clinical decision support tool for pediatric hematologists, oncologists, and critical care physicians during the difficult decision-making process of extracorporeal membrane oxygenation candidacy and management.
Cell Therapy News
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
[New England Journal of Medicine] In a Phase III clinical trial, scientists randomly assigned, in a 1:1 ratio, patients with large B cell lymphoma that was refractory to or had relapsed no more than 12 months after first-line chemoimmunotherapy to receive axicabtagene ciloleucel or standard care.
Cell Therapy News
Emerging Strategies for Beta Cell Transplantation to Treat Diabetes
[Trends in Pharmacological Sciences] Beta cell replacement has emerged as an attractive therapeutic alternative to traditional exogenous insulin administration for management of type 1 diabetes.
Extracellular Matrix News
Recent Advancement of Decellularization Extracellular Matrix for Tissue Engineering and Biomedical Application
[Artificial Organs] Investigators describe the decellularization and sterilization methods that are commonly used in recent research, and the effects of these methods upon biologic scaffold material.
Hematopoiesis News
Novel Therapeutics and Targets in Myelofibrosis
[Leukemia & Lymphoma] Scientists discuss the limitations of currently approved treatment options and novel therapeutic targets with drug candidates in late-stage, Phase II or III, clinical development for the treatment of myelofibrosis.